FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

APP	

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See In	struction 10.			
1. Name and Address of Reporting Person* Brewer Joanna Elizabeth			2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) C/O ADAPTIM	(Last) (First) (Middle) C/O ADAPTIMMUNE THERAPEUTICS PLC		3. Date of Earliest Transaction (Month/Day/Year) 02/20/2025	X Officer (give title Other (specify below) Chief Scientific Officer
60 JUBILEE AVENUE, MILTON PARK			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
(Street) ABINGDON	X0	OX14 4RX		X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111501.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Option to purchase Ordinary Shares	\$0.1 ⁽¹⁾	02/20/2025		A		1,612,032		(2)	02/20/2035	Ordinary Shares	1,612,032	\$0	1,612,032	D	
Option to purchase Ordinary Shares	\$0.0013 ⁽³⁾	02/20/2025		A		1,074,696		(4)	02/20/2035	Ordinary Shares	1,074,696	\$0	1,074,696	D	

Explanation of Responses:

- 1. The exercise price was converted from GBP0.08 based on an exchange rate of U.S.\$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- 2. Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029.
- 3. The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.\$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- 4. Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February 20, 2027 through February 20, 2029.

<u>/s/ Joanna Brewer</u> <u>02/20/2025</u>
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.